Cigna Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cigna Investments’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-381	Closed	-$214K	–	470
2022 Q1	$214K	Sell	381 -117	-23%	-$70.5K	0.03%	546
2021 Q4	$377K	Sell	498 -215	-30%	-$161K	0.03%	447
2021 Q3	$533K	Buy	713 +45	+7%	+$33.7K	0.04%	405
2021 Q2	$430K	Sell	668 -200	-23%	-$122K	0.03%	465
2021 Q1	$496K	Buy	868 +59	+7%	+$34.9K	0.03%	448
2020 Q4	$472K	Sell	809 -14	-2%	-$7.97K	0.04%	427
2020 Q3	$424K	Hold	823	–	–	0.04%	388
2020 Q2	$372K	Buy	823 +200	+32%	+$88.3K	0.04%	480
2020 Q1	$219K	Hold	623	–	–	0.03%	541
2019 Q4	$224K	Sell	623 -105	-14%	-$37K	0.02%	599
2019 Q3	$242K	Buy	+728	New	+$237K	0.03%	591
2018 Q2	–	Sell	-874	Closed	-$219K	–	736
2018 Q1	$219K	Buy	+874	New	+$223K	0.01%	745

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cigna Investments's BIO Position: Q2 2022 in Review

Cigna Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 381 shares — an estimated $214K sold.

Cigna Investments first reported a position in BIO in Q1 2018 and held it in 12 quarters. The position peaked at $533K in Q3 2021. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Cigna Investments reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Cigna Investments sold 381 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $214K.
Cigna Investments first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 12 quarters.
Cigna Investments's Bio-Rad Laboratories Class A position peaked at $533K in Q3 2021.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Cigna Investments's 13F filing for Q2 2022, filed 15 Aug 2022.